APYX - Earnings call transcript Q1 2021 | Apyx Medical Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the First Quarter of Fiscal Year 2021 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as our most recent 10-Q filing. updated SEC, to our which be filings in website. may the with are factors from time time our Such available on forward-looking otherwise. We or of to obligation information, statements our new or undertake result as events publicly future a no revise update also to certain will not that financial Accounting Accepted references with accordance in Generally include Principles call measures are This calculated or GAAP. these as non-GAAP measures. to financial refer generally We in non-GAAP with of measures those of available earnings calculated GAAP financial accordance presented in our the on comparable Reconciliations release measures most and portion are the the press Relations to Investor website. to the like now would Mr. over I turn call to Goodwin, and Charlie Chief President Medical's Executive Apyx Officer. go sir. Please ahead,

Charlie Goodwin

Tara to call Semb. Thanks, everyone our Operator. this quarter joined this earnings Welcome, our call. by on Officer, I'm morning first Financial Chief

quick you today's review Let for a with a call. results. our begin me first revenue of provide agenda quarter I'll with

$X.X some this quarter of let's for XXXX, we additional press conclude representing results. our an growth well expectations. total results the first share of the the we're the I'll overview review million long-term the of ahead our revenue growth which quarter In started discussion, was our financial cosmetic provide which of will thoughts then a in our of morning. the detailed review open release with an then progress during pursuing four we towards this questions. before update financial strategic we initiatives I'll get XX% closing guidance surgery market. that, XXXX with in of we updated enhance made our call Tara and With of year-over-year, revenue on Following the our to delivered operational

a challenge COVID-XX continued geographic region, noteworthy environment, was disruption given performance saw X% the created the decline our U.S. of offsetting to more $X to than business, by decreased revenue By detailed pandemic, in XX% more million. Advanced business strong by we the overall the sales U.S. global was which in XX% Energy internationally. the OEM in both total that Advanced increased adoption operating year-over-year to and especially of of technology which the XXX% year-over-year was and our key increase encouraging pleased exclusively by sales our sales $X.X in markets million while sales $X.X year-over-year international to Energy our utilization generators driven around which I'm reflecting our XX% growth world. total modest of report $X.X products, increased Shifting handpieces driven to increased the year-over-year in to revenue total million, year-over-year discussion both to sales and Advanced total Energy million. our a Our The our year-over-year

the As COVID quarter despite we we March, volumes on internationally, handpieces see demand in strong the in from countries. of with cases our first earnings the distributors our in many during utilization our to coupled call continued U.S. of mentioned elevated

Our total year-over-year. over Advanced handpiece Energy sales XXX% ultimately by grew

that remain to handpiece in remain generators growth, the and uptick Advanced internationally given the Advanced of addition equipment and persisted December, the see U.S. base continues existing of to COVID global which year-over-year. strong We XX% COVID our the February. especially utilization into sales respect sales demand challenged both created the growth of business, surgeon from cosmetic year-over-year, strong despite With pleased our effects January XX% month uncertainty pandemic. increased Energy Energy the during by to customers our environment with In than generator by in strong our purchasing by and more domestically were capital the to quarter total cases handpiece

COVID. each continued month month with of engaging new potential The Our saw customers the challenged process growth existing trends open being accounts U.S. we the March quarter, of active by in and U.S. improving year-over-year throughout strongest. remained with QX of and the to in be

QX first headwinds these quarter to the the U.S. onset sales return generator sales deliver the since sales ultimately the quarter, growth XX% in team enabling for of year-over-year. COVID U.S. year-over-year well, did our in in us pandemic. generator our first performed and improve marked exceptionally direct to However, growth

pockets sales we evenly the we our by of was our to as XXXX was of growth generator in first Importantly, of from in impacts as second strong XXX% to the in across reflect well, given many quarter U.S. was up Advanced the first generators, XXXX, periods to U.S. Energy driven XXXX driven in more in easier and contributions versus the sales U.S., in aided sales trends countries while underlying two to behind demand But XXXX. international comparison growth which XXX% Energy sales U.S. difficult growth QX, growth an were our part first of growth the strength recovery Advanced in to our generator international in overall during the countries. largely sales our more QX in increased than very quarter to The in distributed handpiece with XXXX utilization results based of was characterize Taiwan, countries of year-over-year, and the pleased XXXX, strong important than to see quarter quarter by were certain up handpiece entered first Brazil sales quarter. strong was generator XXXX. to With distributors of strong, COVID our multiple March XX% which while respect and business compared performance. pace of in QX year-over-year regions, International XX% handpieces the increased prior-year QX compared U.S. respect more by our continued sales and overall. With outside lag which fueled and both the remains

given impact to compared year, Our XXXX. growth benefited increase sales the see COVID and in pleased March from first comparisons of X% easier February to the generator sales but international of last quarter we were of

surgery long-term Apyx to success for Turning to sustainable initiatives our progress review the market. towards cosmetic continued quarter position a Medical during and operational of the in strategic our first four growth

our new the evaluating In strategy clinical continue procedures product procedures U.S., obtain the dermal anticipated. laxity regulatory the targeted our to use U.S. two surgery indications internationally. pursue skin registrations securing had Renuvion we clinical of in to continue countries studies IDE specific while and cosmetic progress in resurfacing, First, to as we for in

the first XX-day visits quarter, dermal we enrolled the During patients for completed study. follow-up in our resurfacing

submit team XXX(k) our on which to clearance, Our preparing request is of track this the for month. we're end still by

study complete track X quarter of Phase the in the We XXXX. XXXX. use we in December We also procedures patients the initiated neck X our of region, evaluating enrollment in Renuvion made of in which of third IDE skin important of enrollment in laxity Phase submental in and to remain on progress

our Turning Plasma first continue in to obtaining Technology countries our global during Europe, two new to strategy, well commercial in our our regulatory the quarter. OUS by clearance as as Africa regulatory for footprint regulatory Eastern team South Helium expand

of treated Dr. spots resurfacing authored yielded COVID-related reviewed appearance. comparison our Journal we pores, on wrinkle brown resurfacing of we well second contribute pass the initial Cosmetic distributors in two area do technology Renuvion we study quarter, market. year. we're prior success Dr. countries he expand aspect months and cosmetic initial by Renuvion. disruption published found them with Holcomb qualitative J. David improvements a this following this on quantitative analysis, Dr. modestly a our see as performance skin in was not achieve and by our initiative, to the at markets part from Dermatology, which notable and regulatory and of both IDE the international of continued orders in expect Advanced XX With pleased in strategic we to setting quantitative in to as procedures. the in energy performed the While a materially said, the With article our surgery use to were strategy, which Renuvion new subjects our regions. our focused of progress focused to in Based continue as on of is saw evidence our number in this these that dermal benefited on Holcomb, the growth during QX, Energy treatment believe portfolio with article to In the in facial of pleased of and continued customer single to Holcomb. The peer our adoption given March, three Renuvion dermal for analysis respect of driving these that clinical low thickness enlarged

this on Specifically, average. new this the we XX%, In brown additional spots target the X% regulatory decreased adoption, this of decreased thickness clinical of clinical our area pores enlarged number which decreased number short, wrinkle by publication clearance receipt by will by validation, U.S. expect decreased support following wrinkle procedure. provides of review peer and for XX%, by XX%,

strategic third initiative. our to Turning

our surgeon events interest of together hosted to for in supporting three progress their continued new the potential open our more the cosmetic three our quarter, events and our customers clinicians strong Working we and commercial KOLs, both technology. and in than During some saw surgery participation top virtual educational XXX and in-person practices. and organized were and to customers. make and reflecting surgeons team These new existing with

team on our Plasma Our OUS five Helium of Technology. our also hosted distributors further to virtual sessions educate training some

and surgeon existing expand enhance of customers. to continue also portfolio We our materials our for marketing

the can wall of of our be from marketing they quarter, including with April, than in-office with used customer-focused forward. the key on Renuvion programs. top XX existing raise clings Users The event planning around and discussions early moving can customer which the portal from launched kit we're awareness featured roughly customers hosted event variety This two-day surgeons entire of kit, leaders In customers, customers hosted base that online our providing Meeting Renuvion we access an kit XX a provides an scrub is events to countries. and new materials, During marketing benefits via and need our caps First them help to all organize available surgeon and portal. a our online presentations we which brochures, world, to for Likewise, event on by that more demand on to opinion introduced users customers technology. half includes their educate which participation and now everything we access branded representing our

through technologies and fourth our improvements further and team Bulgaria. our regarding continuing our manufacturing improve manufacturing handpiece efficiencies at facility production introduction Lastly, our to and the capabilities of and Clearwater manufacturing initiative new drive efficiencies, by our of is in to manufacturing capabilities facility, in our approving final overall the Sofia, strategic capabilities

seen benefits strong were strategic performance early of quarter first the of margin this of execution Importantly, team initiative in strong XXXX. gross our the in

years on adoption of the reducing in our in expected is our unit Specifically, our going handpieces material cost drive handpieces margin, the per APR to focus and forward. Energy improvements our of Advanced gross recent manufacturing handpiece increases

customers in our first in a by driven markets, as to reminder, from efforts XXXX, to U.S. necessary, North sales balanced our key our We to focus customer in start focused on introduction quarter of a introducing product marked securing XXXX. to Advanced As demand generators, before well XXXX sales commercial all, years our including coming our and saw and encouraging come. adoption business, registrations markets utilization requisite All international OUS growth expanding handpieces great America. growth the in the where In as from in this in year-over-year we're internationally. and strong Energy contributions total trends to and in the

strategic progress translated and the positioned prior-year over four gross EBITDA activities our strong deliver long-term. compared period. sustained total And margins in the performance to in to growth to our us year-over-year loss initiatives better related strong to into leaving sales our our smoothly, improvements adjusted continued Our improvements

With to Our a efforts obstacles quarter, their their as Tara? call any for and guidance. cosmetic we updated me Helium overcoming our Plasma our the thank the this over commitment and results I'd market to with to moment surgery our quarter to turn take team to them Tara an first exceptional Technology. demonstrated financial did job discuss that, they've and revolutionize let like XXXX

Tara Semb

Charlie. Thanks,

to X% between increase $X.X million P&L. for first by or quarter by first decrease Given $XX.X of and margin XXXX for Charlie's million the offset review $X.X operating of million of Gross million our services, results or the quarter down continuing first expenses detailed compared selling, million in Net to of mix, our geography segment, first The million, XX% to compared improved that XXXX. financial last for in was quarter year. total was very of XXXX the million Gross profit year-over-year increased by continued our million XX.X% year-over-year results, $X.X year-over-year the I'll loss income for year-over-year expenses and income a which expenses and and margins benefits in by in of year-over-year and in the gross $X.X mix in of costs Income benefit on the change was of as in first research not for which our quarter The offset well partially of to refunds of loss of paid $X.X million. increased discussion benefit was of driven spending, to tax our revenue profit due The tariffs was primarily the two related first initiatives expenses XXXX. operating financial financial to revenue first $X a in as margins initiatives Charlie Advanced our revenue to The from compared in per $X.X claim the first Total of compared the benefit quarter on of other compared year-over-year $X.XX and margins reduce operations refunds costs benefit by XXXX from loss segments last of partially the in in XXXX operating to first recognized to quarter $X.X operating from decrease of in quarter quarter XXXX of increase increase million the product a results expense in product. stockholders salaries professional did gross of the manufacturing earlier. was million $XX.X administrative was receipt quarter XX.X% Energy efficiency mentioned last of did by a quarter profit reflects our QX and increase XXXX $X.X begin for to expenses. increase compared the $X.X of first attributable my control Operating carryback tax profit XXXX. million in The $X.X increase continued net modest the quarter the general our condition. first by $X.X to other XXXX. due development year-over-year and share the was quarter expense million began to $X.X a quarter the quarter The XXXX impact the quarter million, or XXXX, XXXX the of our million share, in due change which $X.X per primarily net to XXXX, COVID-XX not in $X.X million, for Loss first in $X.XX financial or discretionary was first in to results the year. response was XXXX. second million year-over-year loss for year. first driven

First quarter EBITDA of was year, last improvement an million $X.X XX% million loss year-over-year. loss compared or to a million XXXX $X.X $X.X adjusted of

loss from EBITDA As a reconciliation a this detailed net we in provided GAAP press our reminder, to adjusted morning. loss release

as cash XXXX, the compared As had equivalents XXXX. of cash XX, XX, million, of and $XX.X March to million company $XX.X December of

the during CARES loss company XXXX related the company the that million resulting the of March operating Act. refunds $X.X had expected to carrybacks XX, working anticipates net from XXXX, $XX.X to of of XXXX tax As million, approximately including capital receive

XXXX we updated Turning to morning. review which of financial earnings in our press our release a guidance, this

international we in of representing driven to December compares $X.X this the revenue our total of approximately the from following $XX.X to Renuvion range Energy XX% updated growth related the range sales now range $XX.X updated prior and approximately $XX.X $XX.X coagulator Advanced growth of by revenue year-over-year, The representing as revenue to compares assumes to to use, XX% million continues only primarily Energy revenue a million, million Advanced year-over-year. range $XX.X growth to subdermal growth a The range $XX.X million ending from by For XX-months range. driven to guidance million. revenue million demand This $XX.X to million, XX% decline XX, expect This representing of in range procedures U.S. liposuction guidance XXXX, of assume million international contributions to its of total XX% year-over-year. existing OEM our to in is XX% prior is guidance guidance $XX.X our markets. of unchanged prior guidance million. of

to we our for range This guidance prior of of profitability of stockholders year million in fiscal our to range net the loss $XX terms of million guidance million. EBITDA to adjusted compares million expect attributable loss In of $XX.X in prior range guidance $XX.X million $XX.X million. to the $XX.X XXXX, $XX.X This we $XX.X to And million. range million. expect $XX to compares to

to a net have in EBITDA we included GAAP a loss loss from adjusted our our this As press reminder, reconciliation earnings release non-GAAP morning. full

to the guidance financial incorporate formal modeling Our XXXX considerations purposes. following for continues for

the total full-year Energy our company be growth assume period exclusively driven revenue business. our XXXX by for Advanced First, we will

strong U.S. midpoint growth Advanced compared of to Advanced growth to Energy expect to internationally and up in guidance our XX% U.S. Energy customers guidance now growth the and International and sales year-over-year in XX% prior XX% We Energy range both Advanced XXXX respectively. sales and which assumes our XX% Energy in Advanced growth roughly assumes the roughly customers in

in range this last continued and gross we geography our by handpiece. our segment XX.X% primarily by by APR year Second, handpieces, including efficiency to the driven XX% to to the manufacturing continued initiatives mix expect product, for margins benefits continued XX% compared year of specifically, by

we our we expect China, last in to compensation-related established reductions, travel as $X.X we expenses approximately plus operating year. guidance normalized incremental in of expense driven and expect expenses of to and initial net approximately aforementioned And of benefit range million, benefit carryback to expense shares. assumptions non-cash expense of joint compared in of net $XXX,XXX interest Fourth, diluted venture in million, approximately $XXX,XXX year. expenses XX% loss result XXXX to compensation Act. compared tax of the GAAP shares now XXXX, $X.X year, income by stock-based $XXX,XXX expect and XXXX expense operating tax average expense, that which $X.X $XXX,XXX, other GAAP in $XXX,XXX roughly a increase the sixth, expect approximately compensation entertainment, which operating $X.X tax operating approximately Fifth, to $X.X expectations. weighted increase included XXXX million other last of in discretionary, of outstanding approximately related stock-based and partnership including of operating million our benefited the continue CARES increase a which approximately and our of growth from the GAAP benefit million we our our expense XX amortization Third, and income to expenses, of mid-single-digit revenue expense million year-over-year, depreciation now COVID-related we excludes non-cash last an Accordingly, approximately

our to This revenue the that, Lastly, standard quarter XX% revenue practice call year-over-year. a and impact significant while XXXX, rate in of XXX% the avoidance for growth decline With back I'll in the of the benefits in given our remarks. assumes closing the expectations, XXX% range in of XX% of it is our to approximately OEM pandemic to second provide of we total second Advanced XXXX increase the and QX of COVID expect related turn XXX% the to XXX% approximately revenue year-over-year. growth of total XXXX transparency, doubt interest to the year-over-year approximately not quarterly Charlie quarter Energy for and to Charlie. to

Charlie Goodwin

to evidence, this and With performance sheet, call well of supported continues market by on for differentiated as cosmetic outlook our trends the clinical We seen for months. continued a opportunity, momentum their XXXX positioned exceptional portfolio global work, that distributors to the utilization now to support solid Thanks, balance continuing and and Apyx let's customers, a well that global global dollar Apyx to open our and sustained Medical in an year for technology environment as as the and expanding confidence Tara. encouraging the in player We're adoption growth forward as multi-billion drive to our market. surgery nine improving Medical for we as revenue including look our well remaining remain have hard reflect strong, our for the mission. investors building we as to their by our both we deliver we financial strong have execution start as establish guidance and leading the performance to the again I'd year, raising like a With questions. our for financial thank recover. recent strategic continued operator, employees addressable

Operator

will Thank from come our Securities. [Operator Dave JMP you. Instructions]. from Turkaly And first question

Dave Turkaly

the congrats know how different I saw you the morning I are broad geographies that this has the the across on Good strength was, I love on be sort stands given to we've to get of we always growth product assume generators, asked handpiece the I'm larger getting and a and lines. been got to between that before curious, component, capital closer and Charlie, just it's that level. if just your mix XX:XX. and and thoughts but today where approximating balanced

Charlie Goodwin

in side. of We U.S. generators appreciate light question. growth, year-over-year. was it still generator were pandemic up we our the U.S. first with were Thanks, in on incredibly up exist. Dave. XX% Yes, it And we and in happy being about the very quarter that COVID-related the Yes. challenges our QX generator year-over-year And of particular the growth XX% in as still talked impressive with had was the sales

still And U.S. -- measured markets. from generator our grew demand On that, our up from but quarter-over-quarter were X% in we XXX% operating easy by countries comps. reflects remember, certain XXXX. operating But we improvement OUS the benefited over in year-over-year, side, environment environment multiple

about talking very obviously Renuvion. future. continued that far about as adoption the of with incredibly But that It mix seen exact handpieces, globally are the -- the the growth As utilization makes is in to exciting us very us be going we've we're we and not of and for we're confident to detail. generators happy and

Dave Turkaly

to follow-up international on you a that. had guess day. then a Yes, for I front. And Thank that. I And the it I drive appreciate as

been other you call and I sequentially. guess, the You very but quarters strong Brazil last a on Taiwan obviously side, two that's across strengthen, and Hampi that mentioned countries generator,

maybe even side particularly generator us additional be any color So helpful? I would on might there, you the give guess

Charlie Goodwin

when -- get more demand strategy Well, and go talking had talking countries, about new in those those when we be in we've to our countries. that two you're I countries, that about particular, to lot going when those because there's the generators into you're right a that long-term place, of there's think regulatory get obviously,

And been we've here about obviously three to adoption talking so we this then then since handpiece we've starts, now, utilization has been strategy And for keep been strategy countries, but years. that generator new a as the continue adding follows.

areas bag mixed some outside they're is a the countries COVID affected still how like are all a really so And United up about being and United States business more it outside predict than vaccine And more as that recovering, is outside the the things really it could nice United this But the COVID than you is to to way States from and really we others. outside behind so. starts United build growth see of a with hard the adoption on handpiece perspective, that, really, of with States talked certain and XXX%. that States the and

Operator

from next Our Craig-Hallum. comes Hewitt with question Matt

Matt Hewitt

Good morning. the Congratulations and for efforts. on to a was the hoping on bit strong sales marketing quarter. little couple focus I questions me A

year? should in As starts see to are costs out about up we How customers? and of ramping able a thinking decline. into about you out those as Are sales some get get of perspective, OUS you as to pockets know, the your more from of COVID rolled the vaccines course over here domestically

Charlie Goodwin

Yes.

And despite quarter selling having this with United very finally States, the very the we we in were the in that and generators, specifically made were progress COVID. we growth much in QX front in on active pleased the that So first again.

was We had. first actually trade have in-person in that just actually very started show I it the April; think

United attended in-person then trade hosted was and shows. that expect because in-person have more about by we event as would and PMP docs. was the go in And our it so virtual we hybrid see that was to XXX forward But we and as wonderful, can you States a for it

hybrid so in-person seeing the virtual. a and same And and the we're is -- shows there thing that's of that trade thing with

I traveling start so see those rest things that start those as to that of And we more attending of you year. of we increase And year, go-forward of the to through more obviously more you'll in this a our think see the Tara, think and more will lot I expenses as start things, of an that.

Matt Hewitt

resurfacing Got it. it campaigns. to it assume safe QX, really couple that drive some the safe add a follow-up And sounds in sales be to QX of early it assume market dermal would approval, Thank sales marketing team be you then you on that a received the that, headcount to like you. some maybe would just that resources, new approval. the you've to after launched Would growth

Charlie Goodwin

Yes, a good question.

anticipate So the from to for continue least We this target dermal I of we at from mentioned by we end earlier, XX resurfacing month. as -- XXX(k) study, our decision the days FDA. -- the

with launch But XXXX. expect our on from full the plan the now. include in potential material August sales not any together comfortable for And that contributions have we do dermal wouldn't a contributions launch in until during limited revenue commercial salesforce for guidance organization really We and right perspective of size we to XXXX we're sales getting resurfacing. does prepare the in plan Our a from QX.

Operator

Sandler. is Piper next Matt from Our question O'Brien of the with line

Korinne Wolfmeyer

Hi, the is Korinne Matt. this congrats for questions Thanks the on taking for and quarter. on

with So U.S. you bit with than why unchanged? QX guide, to little to change we that anticipated. first had you've business better trends of just doing guidance and in the looking segment OEM at speak the got your just seen some no the a despite Can

Charlie Goodwin

the you question. thank for -- I Well, Yes.

what for -- right we quarter. For guidance in had the the was OEM, first it's our

And we expected decrease the XXXX and quarter approximately assumes revenue, where business -- in which QX. million So we $X.X QX. first results right, and would be the did that after we in basically what we $X of had million thought are guidance million XX% for $X had the a is our

it $X.X was was million And these always business demand has what asked and these last because But million trends our down obviously no change aesthetic space. to this the there a this OEM talked the in environment and are from that COVID, did partner, right hospitals driven the million in really about being when impacted year. is it our we Remember, hospital us, OEM in market why do by is revenue. about sold primarily sell business. that's remember here to we've on been for the So We're forecasting $X it than year. more expected $X.X It year. COVID you why, it by customers globally

Korinne Wolfmeyer

year are Great. the helpful. about should XX% it Any or range? would then margin to improvement think gross it ramp little be a And Should that to now Thank how front, on the That's a lumpy? sequential to helpful. just like on be will the where color throughout good you. that pretty bit we from get be we XX% up

Charlie Goodwin

Yes.

So United gross that seeing to if you we last APR product out driven by our and and mix the year specifically adoption mix it was And States. APR our and the the obviously that outside by margins, product in just primarily for on we're remember the the States, the United do we handpiece. U.S. started segment and the rolled of in

in of outside sold last has outside have the of the States, quarter -- we'll the obviously quarter would than that in the so the United States year, we we will And year. the United first expect more APR

on so drive ramp margin basis. will help sequentially that the gross And that quarter-by-quarter a

Operator

you. [Operator Thank Instructions].

the RENN Capital. sir. Our next line Please with your Russell question, Cleveland proceed from with is coming question of

Russell Cleveland

quick much so couple great A questions. Hi the numbers. gang, thanks for of

at lot growth, we're a international you the not, Can international your how places example, and places the that looking we're like so world and these scale forth. now? of there's that on not comment for on Argentina First we're

Charlie Goodwin

had some timing are the strategy by guidance we strong things. than new exciting. as also a working OS a countries aren't from given So fast the comment of we're we're three has these that growth been been is doing. on in lot this to far in get control do multi-year only their of this and to because is -- into -- but countries. strategy And real baking of of especially to growth the allowing of in really XXX% existing just new to And growth we not a the obviously, countries. the that adding Russell, never very are as we countries, a then testament And it, registrations timing for of we get COVID that. our that of a that us -- which assumes they're on you And ministries of lot these for new team But know quarter, can, not really regulatory environment as and of COVID we've work is we a because hampered the focused health we're OUS control our more were keep as our internationally on when something as we able of obviously lot encouraged and others registrations, these we it,

Russell Cleveland

second which call question, Okay. which I My -- we FDA facelift. it's, are resurfacing, the dermal on

we our Now just that's correct? being done, currently that with speak is being regulatory approval, that's don't we the performed technology, but have as

Charlie Goodwin

it. Yes. It is an it do not we promote procedure. and off-label promote cannot We

being is it done. So

decide wait to they to want of They use are can for But before clinician that You're lot off-label. a to. correct, that use company actually use a clinicians will the that an it. way the there the indication for not get technology technology actually because they any

done actually it an being in And is is that we organization being So is marketplace do yes, today. something done, not promote it but it commercialize as off-label. or the

Russell Cleveland

approvals would a you the of it really, our that and marketing and that where next and indicated going be or is completion So earlier hopefully are? spoke get fourth quarter campaign this would really about into year before that; the launch study, -- we in we

Charlie Goodwin

Yes.

to soft be you August certain quarter start to to on month. the will would end we dermal product resurfacing. XXXX. and fourth the do launch. launch from together plan a material get by planning And launch to for our we a a towards submit the for in we when process end of XX-day is this at after So salesforce it least the the expect It We in then track always that revenue have that then a of then soft that are XXX(k)

Russell Cleveland

Great. ends for questions. Thanks the again numbers. my That

Charlie Goodwin

Thanks, All right. Russ.

Operator

currently are at questions your showing participation. no this you today. And conference does conclude We Thank time. Thank remaining for you. for our that

Charlie Goodwin

you. Thank

Apyx Medical (APYX) 12 May 212021 Q1 Earnings call transcript